Since LRTs increase the levels of hypoxia-induced factors, such as VEGF, and due to the well-known antiangiogenetic and cytostatic activity of sorafenib, the combination therapy has the theoretical potential to synergically improve the efficacy in decreasing tumor burden. This evidence concerns the gene VEGFA and neoplasm.